Cranbury-based Amicus Therapeutics announced Thursday two new additions to its senior leadership team.
Jill Weimer, a developmental neuroscientist has been named senior vice president of discovery research and gene therapy science, and Simon Jordan, a biotechnology industry executive, has been named senior vice president of international.
Wiemer will report to Hung Do, chief science officer and Jeff Sastelli, chief portfolio officer and head of gene therapy. Jordan will report to Bradley L. Campbell, president and chief operating officer.
“On behalf of the Senior Leadership Team, I am pleased to welcome Dr. Jill Weimer and Simon Jordan to Amicus,” John F. Crowley, chairman and CEO of Amicus, said. “Jill is a trailblazer within the field of gene therapy science. All of our gene therapy programs for Batten disease originated out of Jill’s research lab, in collaboration with Dr. Brian Kaspar and Dr. Kathrin Meyer at Nationwide Children’s Hospital. Jill will be a valuable leader to advance our Amicus gene therapy science and platforms for rare devastating diseases. Adding additional strength of our senior team is Simon Jordan, who will be instrumental as we continue to grow our international operations. Simon’s leadership responsibilities will include the important expansion of our Galafold commercial business and global clinical studies, as well as pre-launch activities for therapies advancing in our pipeline, including the potential for AT-GAA to become the new standard of care in Pompe disease. Both Simon and Jill have demonstrated a deep commitment to our mission to develop groundbreaking new medicines and deliver them to people living with life-threatening conditions as quickly as possible.”
Prior to her appointment, Weimer led a research team at Stanford Research. She will continue to work with Stanford to support ongoing preclinical Batten disease programs in addition to her new role.
Jordan joins Amicus from Biogen, where he most recently served as regional vice president. He was with the company from 2005 to 2018. Before that, he held marketing roles at Abbott.
